Specifically, HT patients harboring BRAF mutant PTCs were less likely to develop central (OR = 0.42, 95%CI = 0.19–0.92, p = 0.030) and lateral LNM (OR = 0.24, 95%CI = 0.08–0.75, p = 0.014) compared to the patient cohort without underlying HT. Here, BRAF is linked to hematocrit.